<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293447</url>
  </required_header>
  <id_info>
    <org_study_id>14-8053</org_study_id>
    <nct_id>NCT02293447</nct_id>
  </id_info>
  <brief_title>Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization</brief_title>
  <official_title>Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine artery embolization (UAE) is a minimally invasive treatment for women with
      symptomatic fibroids. It is similar to hysterectomy in term of satisfaction and symptoms
      improvement, with fewer complications and at lower cost. However, the majority of women
      undergoing UFE experience important pain after the procedure despite optimal analgesia, with
      one third reporting pain equal or worse than labor. Pain is the more common cause of
      prolonged hospital stay or readmission. There is need for a simple, efficient way to reduce
      post-procedural pain.

      For this prospective randomized study, the hypothesis is that an anesthetic drug, lidocaine,
      injected in the uterine arteries diminishes pain post-UFE. Patients will be randomized in 3
      groups: control, lidocaine injected during embolization, and lidocaine injected after
      embolization. Pain will be evaluated using a validated scale at 4h and 24h post-intervention.
      Hospital length-of-stay and total narcotic dose administered will be evaluated in the three
      groups.

      This is the first Canadian study evaluating lidocaine use for pain control in UFE patients.
      Results will be transferable to clinical practice, considering the use of lidocaine is simple
      and cost is negligible. It could have a great impact on pain management in women undergoing
      UFE in all practice settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Procedural Pain at 4 hours</measure>
    <time_frame>4h post-procedure</time_frame>
    <description>Pain will be evaluated using a validated 100mm Visual Analog Scale (VAS) filled by patients at 4h, 7h and 24h post-procedure. At 4h, patients will report the worst pain they experienced since end of procedure. At 7h and 24h, pain at time of assessment will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Procedural Pain at 7 hours</measure>
    <time_frame>7h post-procedure</time_frame>
    <description>Pain will be evaluated using a validated 100mm Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital length-of-stay</measure>
    <time_frame>24 hours post-intervention</time_frame>
    <description>Estimated in hours, the length-of-stay will be evaluated from the end of procedure to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic dose</measure>
    <time_frame>24 hours post-intervention</time_frame>
    <description>The total amount on narcotic doses administered to patient during the first 24hours post-procedure will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Procedural Pain at 24 hours</measure>
    <time_frame>24 hours post-procedure</time_frame>
    <description>Pain will be evaluated using a validated 100mm Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Uterine Leiomyomas</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine per-embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine post-embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine per-embolization</intervention_name>
    <description>10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.</description>
    <arm_group_label>Lidocaine per-embolization</arm_group_label>
    <other_name>Local anesthetic</other_name>
    <other_name>Amide-type anesthetic</other_name>
    <other_name>Lidocaine hydrochloride</other_name>
    <other_name>00884154</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine post-embolization</intervention_name>
    <description>10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.</description>
    <arm_group_label>Lidocaine post-embolization</arm_group_label>
    <other_name>Local anesthetic</other_name>
    <other_name>Amide-type anesthetic</other_name>
    <other_name>Lidocaine hydrochloride</other_name>
    <other_name>00884154</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for uterine fibroid embolization: bulk symptoms, pain or heavy menstrual
             bleeding attributed to fibroids, with imaging confirmation;

          -  Patient must be able to provide written, informed consent

        Exclusion Criteria:

          -  Documented of allergy or intolerance to lidocaine or other amide-type anesthetics;

          -  Personal or familial history of malignant familial hyperthermia;

          -  Documented history of second or third atrio-ventricular heart block

          -  Contra-indication to uterine fibroid embolization : active infection, suspected
             malignancy, coagulopathy, pregnancy or desire to preserve fertility, large
             pedunculated sub-serosal fibroid.

          -  History of previous uterine fibroid embolization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dheeraj Rajan, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.uhnresearch.ca/reb/rebcontactus.htm</url>
    <description>UHN research ethics board contact information</description>
  </link>
  <link>
    <url>http://www.webmd.com/women/uterine-fibroids/uterine-fibroid-embolization-ufe</url>
    <description>Description of uterine fibroid embolization procedure</description>
  </link>
  <reference>
    <citation>Keyoung JA, Levy EB, Roth AR, Gomez-Jorge J, Chang TC, Spies JB. Intraarterial lidocaine for pain control after uterine artery embolization for leiomyomata. J Vasc Interv Radiol. 2001 Sep;12(9):1065-9.</citation>
    <PMID>11535769</PMID>
  </reference>
  <reference>
    <citation>Zhan S, Li Y, Wang G, Han H, Yang Z. Effectiveness of intra-arterial anesthesia for uterine fibroid embolization using dilute lidocaine. Eur Radiol. 2005 Aug;15(8):1752-6. Epub 2005 Feb 5.</citation>
    <PMID>15696287</PMID>
  </reference>
  <reference>
    <citation>Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003 Jan;188(1):100-7.</citation>
    <PMID>12548202</PMID>
  </reference>
  <reference>
    <citation>Pinto I, Chimeno P, Romo A, Pa√∫l L, Haya J, de la Cal MA, Bajo J. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment--a prospective, randomized, and controlled clinical trial. Radiology. 2003 Feb;226(2):425-31.</citation>
    <PMID>12563136</PMID>
  </reference>
  <reference>
    <citation>Hehenkamp WJ, Volkers NA, Donderwinkel PF, de Blok S, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial): peri- and postprocedural results from a randomized controlled trial. Am J Obstet Gynecol. 2005 Nov;193(5):1618-29.</citation>
    <PMID>16260201</PMID>
  </reference>
  <reference>
    <citation>Hehenkamp WJ, Volkers NA, Birnie E, Reekers JA, Ankum WM. Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy--results from the randomized clinical Embolisation versus Hysterectomy (EMMY) Trial. Radiology. 2008 Mar;246(3):823-32. doi: 10.1148/radiol.2463070260. Epub 2008 Jan 9.</citation>
    <PMID>18187401</PMID>
  </reference>
  <reference>
    <citation>Volkers NA, Hehenkamp WJ, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years' outcome from the randomized EMMY trial. Am J Obstet Gynecol. 2007 Jun;196(6):519.e1-11.</citation>
    <PMID>17547877</PMID>
  </reference>
  <reference>
    <citation>Ananthakrishnan G, Murray L, Ritchie M, Murray G, Bryden F, Lassman S, Lumsden MA, Moss JG. Randomized comparison of uterine artery embolization (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): subanalysis of 5-year MRI findings. Cardiovasc Intervent Radiol. 2013 Jun;36(3):676-81. doi: 10.1007/s00270-012-0485-y. Epub 2012 Oct 16.</citation>
    <PMID>23070101</PMID>
  </reference>
  <reference>
    <citation>Edwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, Murray GD; Committee of the Randomized Trial of Embolization versus Surgical Treatment for Fibroids. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med. 2007 Jan 25;356(4):360-70.</citation>
    <PMID>17251532</PMID>
  </reference>
  <reference>
    <citation>Moss JG, Cooper KG, Khaund A, Murray LS, Murray GD, Wu O, Craig LE, Lumsden MA. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results. BJOG. 2011 Jul;118(8):936-44. doi: 10.1111/j.1471-0528.2011.02952.x. Epub 2011 Apr 12.</citation>
    <PMID>21481151</PMID>
  </reference>
  <reference>
    <citation>Spencer EB, Stratil P, Mizones H. Clinical and periprocedural pain management for uterine artery embolization. Semin Intervent Radiol. 2013 Dec;30(4):354-63. doi: 10.1055/s-0033-1359729. Review.</citation>
    <PMID>24436562</PMID>
  </reference>
  <reference>
    <citation>Pron G, Bennett J, Common A, Wall J, Asch M, Sniderman K; Ontario Uterine Fibroid Embolization Collaboration Group. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril. 2003 Jan;79(1):120-7.</citation>
    <PMID>12524074</PMID>
  </reference>
  <reference>
    <citation>Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic fibroids: clinical results in 400 women with imaging follow up. BJOG. 2002 Nov;109(11):1262-72.</citation>
    <PMID>12452465</PMID>
  </reference>
  <reference>
    <citation>van der Kooij SM, Moolenaar LM, Ankum WM, Reekers JA, Mol BWJ, Hehenkamp WJK. Epidural analgesia versus patient-controlled analgesia for pain relief in uterine artery embolization for uterine fibroids: a decision analysis. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1514-1520. doi: 10.1007/s00270-013-0607-1. Epub 2013 Apr 11.</citation>
    <PMID>23576212</PMID>
  </reference>
  <reference>
    <citation>Rasuli P, Jolly EE, Hammond I, French GJ, Preston R, Goulet S, Hamilton L, Tabib M. Superior hypogastric nerve block for pain control in outpatient uterine artery embolization. J Vasc Interv Radiol. 2004 Dec;15(12):1423-9.</citation>
    <PMID>15590800</PMID>
  </reference>
  <reference>
    <citation>Guthaner DF, Silverman JF, Hayden WG, Wexler L. Intraarterial analgesia in peripheral arteriography. AJR Am J Roentgenol. 1977 May;128(5):737-9.</citation>
    <PMID>404894</PMID>
  </reference>
  <reference>
    <citation>Widrich WC, Singer RJ, Robbins AH. The use of intra-arterial lidocaine to control pain due to aortofemoral arteriography. Radiology. 1977 Jul;124(1):37-41.</citation>
    <PMID>325598</PMID>
  </reference>
  <reference>
    <citation>Widrich WC, Robbins AH, Goldstein SA, Singer RJ. Adjuvant intra-arterial lidocaine in aortofemoral arteriography: some further observations. Radiology. 1978 Nov;129(2):371-3.</citation>
    <PMID>360272</PMID>
  </reference>
  <reference>
    <citation>Cranston PE. Lidocaine analgesia in peripheral angiography: a confirmation of effectiveness. South Med J. 1982 Oct;75(10):1229-31.</citation>
    <PMID>7123294</PMID>
  </reference>
  <reference>
    <citation>Gordon IJ, Westcott JL. Intra-arterial lidocaine: an effective analgesic for peripheral angiography. Radiology. 1977 Jul;124(1):43-5.</citation>
    <PMID>866655</PMID>
  </reference>
  <reference>
    <citation>Molgaard CP, Teitelbaum GP, Pentecost MJ, Finck EJ, Davis SH, Dziubinski JE, Daniels JR. Intraarterial administration of lidocaine for analgesia in hepatic chemoembolization. J Vasc Interv Radiol. 1990 Nov;1(1):81-5.</citation>
    <PMID>1966862</PMID>
  </reference>
  <reference>
    <citation>Hartnell GG, Gates J, Stuart K, Underhill J, Brophy DP. Hepatic chemoembolization: effect of intraarterial lidocaine on pain and postprocedure recovery. Cardiovasc Intervent Radiol. 1999 Jul-Aug;22(4):293-7.</citation>
    <PMID>10415218</PMID>
  </reference>
  <reference>
    <citation>Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A. Assessment of pain. Br J Anaesth. 2008 Jul;101(1):17-24. doi: 10.1093/bja/aen103. Epub 2008 May 16. Review.</citation>
    <PMID>18487245</PMID>
  </reference>
  <reference>
    <citation>Pron G, Mocarski E, Bennett J, Vilos G, Common A, Zaidi M, Sniderman K, Asch M, Kozak R, Simons M, Tran C, Kachura J; Ontario UFE Collaborative Group. Tolerance, hospital stay, and recovery after uterine artery embolization for fibroids: the Ontario Uterine Fibroid Embolization Trial. J Vasc Interv Radiol. 2003 Oct;14(10):1243-50.</citation>
    <PMID>14551270</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Dheeraj Rajan</investigator_full_name>
    <investigator_title>Attending Interventional Radiologist and Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Uterine</keyword>
  <keyword>Fibroid</keyword>
  <keyword>Embolization</keyword>
  <keyword>Leiomyoma</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

